About US
Contact us
-
Phillips-Medisize buys Denmark’s Medicom Innovation, expanding European presencePhillips-Medisize, a medical injection molder, bought Denmark’s Medicom Innovation Partner, a provider of device strategy, product design and drug delivery systems, in a move to expand its footprint i2016/6/8
-
Novavax presents data on developing seasonal influenza nanoparticles for RSVUS-based, clinical-stage vaccine company Novavax has presented data for the company's nanoparticle programme at the New Approaches to Vaccines for Human and Veterinary Tropical Diseases Keystone Sympo2016/6/7
-
Novartis and Eisai to promote Lenvima in combination with everolimus to treat RCCSwitzerland's Novartis Pharmaceuticals has entered into an agreement with Japanese firm Eisai's US subsidiary to co-promote Lenvima (lenvatinib) capsules in combination with everolimus, to treat patie2016/6/7
-
Filling Semi-solids into Syringes in a Clean, Accurate, and Space-Saving MannerConventional filling techniques in the pharmaceutical industry often see semi-solid and viscous products such as ointments, gels, and creams applied via a dosing syringe. However, the quantities requi2016/6/6
-
Deals this week: Incyte, Sandoz AG, Mylan N.V.Incyte Corporationand Moffitt Cancer Centre have entered a three-year research and collaboration agreement to jointly develop novel therapeutics approaches for hematologic malignancies. According to2016/6/6
-
When to Use FDA’s Pre-Submission ProgrammePharma consultants: Did you know there is a medical device programme that is beneficial to some aspects of drug applications? FDA's Pre-submission programme was formerly known as the pre-IDE (Investi2016/6/3
-
Recordati takes over Italian pharmaceutical company Italchimici for €130mInternational pharmaceutical group Recordati has acquired 100% stake in Italian pharmaceutical company Italchimici for €130m. Recordati has made the acquisition from Progressio SGR, manager of the fu2016/6/3
-
Roche’s MabThera SC receives EC approval to treat chronic lymphocytic leukaemiaSwiss pharmaceutical company Roche has received approval from the European Commission (EC) for the subcutaneous (SC) formulation of MabThera (rituximab), to treat people affected with previously untre2016/6/2
-
EMA recommends marketing authorisations for Epclusa and Zepatier to treat hepatitis C virusThe European Medicines Agency (EMA) has recommended the approval of marketing authorisations for two latest combination therapies against chronic (long-term) hepatitis C virus (HCV) infection in the E2016/6/2
-
EMA recommends marketing authorisations for Epclusa and Zepatier to treat hepatitis C virusThe European Medicines Agency (EMA) has recommended the approval of marketing authorisations for two latest combination therapies against chronic (long-term) hepatitis C virus (HCV) infection in the E2016/6/1